跳到正文
原文
Science Magazine· @ScienceMagazine · X·· 8 天前精选AI 评分65
AI 导读

美国FDA已批准注射用lenacapavir的仿制版本,该药可提供6个月的HIV感染保护。其印度生产商Dr. Reddy's Laboratories承诺以每人每年仅40美元的价格销售,FDA的批准被普遍预期将推动该药在获准销售的国家取得许可。

推荐理由

FDA批准lenacapavir仿制版本,并给出每年40美元的定价,读者可据此判断低成本长效HIV预防在低收入国家的可及性变化。

正文

A decision by U.S. regulators promises to speed the delivery of a powerful HIV prevention tool in low-income countries with high infection rates.

The Food and Drug Administration (FDA) has given its seal of approval to a generic version of injectable lenacapavir, which can protect from HIV infection for 6 months.

Its Indian manufacturer, Dr. Reddy’s Laboratories, has pledged to sell the drug for just $40 per person per year, and FDA’s approval is widely expected to lead to licensing in countries where the company is allowed to market it.

Learn more: https://scim.ag/4fiHGyv @NewsfromScience

来源:Science Magazine · x.com